Research programme: hepatitis C virus therapeutics - Pfizer

Drug Profile

Research programme: hepatitis C virus therapeutics - Pfizer

Latest Information Update: 14 Jan 2013

Price : $50

At a glance

  • Originator Agouron Pharmaceuticals
  • Developer Pfizer
  • Class Gene therapies; Pyrones
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 01 Jan 2013 No development reported - Preclinical for Hepatitis C in USA (PO)
  • 14 Sep 2010 Preclinical trials in Hepatitis C in USA (PO)
  • 04 Aug 2009 No development reported - Preclinical for Hepatitis C in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top